Keros Therapeutics (NASDAQ:KROS) Director Jean Jacques Bienaime Acquires 1,000 Shares of Stock

Keros Therapeutics, Inc. (NASDAQ:KROS) Director Jean Jacques Bienaime purchased 1,000 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were purchased at an average cost of $10.19 per share, for a total transaction of $10,190.00. Following the completion of the transaction, the director owned 17,592 shares in the company, valued at approximately $179,262.48. This represents a 6.03% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jean Jacques Bienaime also recently made the following trade(s):

• On Wednesday, April 15th, Jean Jacques Bienaime purchased 1,000 shares of Keros Therapeutics stock. The shares were purchased at an average cost of $11.70 per share, for a total transaction of $11,700.00.

Keros Therapeutics Trading Up 3.8%

KROS stock opened at $10.41 on Thursday. The firm has a market cap of $206.01 million, a P/E ratio of -3.46 and a beta of 0.94. Keros Therapeutics, Inc. has a 12-month low of $9.69 and a 12-month high of $22.55. The stock’s 50 day simple moving average is $11.13 and its 200 day simple moving average is $14.75.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($1.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.19). The firm had revenue of $0.37 million for the quarter, compared to analyst estimates of $1.93 million. Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 17.04%. On average, research analysts forecast that Keros Therapeutics, Inc. will post -5.19 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on KROS shares. Wells Fargo & Company dropped their price target on Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research report on Thursday, March 5th. Wall Street Zen lowered Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Finally, Weiss Ratings downgraded Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 15th. Three equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $20.40.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in Keros Therapeutics by 3.3% during the 3rd quarter. Vanguard Group Inc. now owns 2,718,777 shares of the company’s stock worth $43,011,000 after buying an additional 87,129 shares during the last quarter. Western Standard LLC grew its stake in Keros Therapeutics by 42.7% during the 3rd quarter. Western Standard LLC now owns 2,189,882 shares of the company’s stock worth $34,644,000 after buying an additional 654,989 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its stake in Keros Therapeutics by 26.6% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 768,425 shares of the company’s stock worth $15,645,000 after buying an additional 161,336 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in Keros Therapeutics by 38.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock worth $7,547,000 after buying an additional 205,022 shares during the last quarter. Finally, Federated Hermes Inc. grew its stake in Keros Therapeutics by 27.3% during the 4th quarter. Federated Hermes Inc. now owns 654,724 shares of the company’s stock worth $13,330,000 after buying an additional 140,564 shares during the last quarter. 71.56% of the stock is currently owned by institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.